Study wrapper · #607
Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases.
Editor's note
This narrative review surveys ghrelin and its synthetic analog hexarelin as GHS-receptor ligands, focusing on growth-hormone-independent effects relevant to diabetes and diabetic heart disease. It highlights hexarelin's reported regulation of PPAR-gamma in macrophages and adipocytes and both peptides' proposed roles in protecting and regenerating pancreatic beta-cells, modulating insulin release, and cardioprotection. As a review it usefully ties together the metabolic and cardiac threads of hexarelin's preclinical literature and clarifies which effects appear independent of growth hormone. It is not primary evidence, and the work it summarizes is overwhelmingly animal and cell-based. Human data would be needed before any clinical conclusions about hexarelin in diabetes.
Plain-language abstract
This is a review article summarizing research on ghrelin (a natural hormone) and hexarelin (a synthetic version) and their potential roles in diabetes and diabetes-related heart disease. Both act on the same receptor. The authors describe how hexarelin may influence a metabolism-regulating protein (PPAR-gamma) in immune and fat cells, and how both peptides may help protect and regenerate the insulin-making cells of the pancreas, affect insulin release, and protect the heart, sometimes through effects separate from growth hormone. The article pulls together the metabolic and heart-related findings for these peptides. Because it summarizes mostly animal and cell studies rather than human trials, its ideas would need human research before any clinical conclusions could be drawn.